121 related articles for article (PubMed ID: 38156953)
1. hccTAAb Atlas: An Integrated Knowledge Database for Tumor-Associated Autoantibodies in Hepatocellular Carcinoma.
Li T; Wang P; Sun G; Zou Y; Cheng Y; Wang H; Lu Y; Shi J; Wang K; Zhang Q; Ye H
J Proteome Res; 2024 Feb; 23(2):728-737. PubMed ID: 38156953
[TBL] [Abstract][Full Text] [Related]
2. Human Proteome Microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma.
Yang Q; Ye H; Sun G; Wang K; Dai L; Qiu C; Shi J; Zhu J; Wang X; Wang P
Mol Oncol; 2023 May; 17(5):887-900. PubMed ID: 36587394
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive molecular and immunological characterization of hepatocellular carcinoma.
Shimada S; Mogushi K; Akiyama Y; Furuyama T; Watanabe S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Arii S; Tanabe M; Wands JR; Tanaka S
EBioMedicine; 2019 Feb; 40():457-470. PubMed ID: 30598371
[TBL] [Abstract][Full Text] [Related]
4. The relationship among Girdin DNA methylation, its high expression, and immune infiltration in hepatocellular carcinoma: Clues from in silico analysis.
Zhang C; Ke Y; Lei X; Liu X; Li H; Shi R; Wang L
Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33660763
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers.
Cheng J; Wei D; Ji Y; Chen L; Yang L; Li G; Wu L; Hou T; Xie L; Ding G; Li H; Li Y
Genome Med; 2018 May; 10(1):42. PubMed ID: 29848370
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
Bai Y; Tong W; Xie F; Zhu L; Wu H; Shi R; Wang L; Yang L; Liu Z; Miao F; Zhao Q; Zhang Y
Aging (Albany NY); 2021 Jul; 13(13):17592-17606. PubMed ID: 34237708
[TBL] [Abstract][Full Text] [Related]
7. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
Tang ZM; Ling ZG; Wang CM; Wu YB; Kong JL
PLoS One; 2017; 12(7):e0182117. PubMed ID: 28750095
[TBL] [Abstract][Full Text] [Related]
8. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
9. dbPHCC: a database of prognostic biomarkers for hepatocellular carcinoma that provides online prognostic modeling.
Ouyang J; Sun Y; Li W; Zhang W; Wang D; Liu X; Lin Y; Lian B; Xie L
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2688-95. PubMed ID: 26940364
[TBL] [Abstract][Full Text] [Related]
10. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and immunological potential of PPM1G in hepatocellular carcinoma.
Lin YR; Yang WJ; Yang GW
Aging (Albany NY); 2021 May; 13(9):12929-12954. PubMed ID: 33952716
[TBL] [Abstract][Full Text] [Related]
12. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
Xu H; Xiong C; Chen Y; Zhang C; Bai D
Bioengineered; 2021 Dec; 12(1):2664-2675. PubMed ID: 34115569
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma.
Zhang C; Li J; Huang T; Duan S; Dai D; Jiang D; Sui X; Li D; Chen Y; Ding F; Huang C; Chen G; Wang K
Oncotarget; 2016 Dec; 7(49):81255-81267. PubMed ID: 27835605
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of methylation-driven genes and pretreatment prognostic factors in patients with hepatocellular carcinoma.
He D; Liao S; Cai L; Huang W; Xie X; You M
BMC Cancer; 2021 May; 21(1):599. PubMed ID: 34034705
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of TBC1D10B as a potential prognostic and immunotherapy relevant biomarker in liver hepatocellular carcinoma.
Fan L; Tang Y; Li J; Huang W
Sci Rep; 2023 Jan; 13(1):335. PubMed ID: 36611046
[TBL] [Abstract][Full Text] [Related]
16. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q
Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157
[TBL] [Abstract][Full Text] [Related]
17. Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma.
Hwang HM; Heo CK; Lee HJ; Kwak SS; Lim WH; Yoo JS; Yu DY; Lim KJ; Kim JY; Cho EW
J Transl Med; 2018 Jun; 16(1):177. PubMed ID: 29954402
[TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma.
Tang H; You T; Sun Z; Bai C
BMC Cancer; 2022 Feb; 22(1):197. PubMed ID: 35189839
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications.
Huang X; Yang C; Wang J; Sun T; Xiong H
Aging (Albany NY); 2020 Mar; 12(6):4970-4995. PubMed ID: 32201399
[TBL] [Abstract][Full Text] [Related]
20. Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network.
Deng Z; Ji Y; Han B; Tan Z; Ren Y; Gao J; Chen N; Ma C; Zhang Y; Yao Y; Lu H; Huang H; Xu M; Chen L; Zheng L; Gu J; Xiong D; Zhao J; Gu J; Chen Z; Wang K
Genome Med; 2023 Nov; 15(1):93. PubMed ID: 37936230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
